Delving into the Latest Updates on GZL-016 with Synapse

Overview

Basic Info

Drug Type

TCR-T Cell therapy

Synonyms

GZL-016

Target-

Action-

Mechanism-

Therapeutic Areas

NeoplasmsInfectious DiseasesDigestive System Disorders

Active Indication

Hepatitis BHepatitis B Virus-Related Hepatocellular Carcinoma

Inactive Indication-

Originator Organization

Guangzhou Lion TCR Co., Ltd.

Active Organization

Guangzhou Lion TCR Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要研究目的是评价研究产品在治疗乙型肝炎病毒（Hepatitis B virus， HBV）相关肝细胞癌（ Hepatocellular carcinoma， HCC）患者中的安全性、耐受性、药代动力学、药效学和初步疗效。研究将分为两个部分，剂量递增研究和剂量扩展研究。确定最大耐受剂量（MTD）或II期推荐剂量（RP2D）。

[Translation]

The primary objective of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the investigational product in the treatment of patients with hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC). The study will be conducted in two phases: a dose-escalation study and a dose-expansion study. The maximum tolerated dose (MTD) or the Phase II recommended dose (RP2D) will be determined.

Start Date-

Sponsor / Collaborator

Guangzhou Lion TCR Co., Ltd.

100 Clinical Results associated with GZL-016

Login to view more data

100 Translational Medicine associated with GZL-016

Login to view more data

100 Patents (Medical) associated with GZL-016

Login to view more data

100 Deals associated with GZL-016

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatitis B	Phase 1	China	Guangzhou Lion TCR Co., Ltd.	11 Nov 2025
Hepatitis B Virus-Related Hepatocellular Carcinoma	Phase 1	China	Guangzhou Lion TCR Co., Ltd.	11 Nov 2025